Emerging Frontiers in Brain-Computer Interface Technology
Artificial General Intelligence robot with a glowing circuit brain.
Elon Musk’s Neuralink and OpenAI-backed Merge Labs are advancing brain-computer interface (BCI) technologies predominantly in the United States.
In parallel, Chinese entrepreneur Phoenix Peng is cultivating competitive initiatives through two ventures: NeuroXess, focused on implantable BCIs, and Gestala, which is pioneering non-invasive ultrasound-based interfaces.
Gestala has successfully secured $21.6 million (CN¥150 million) shortly after its inception—a valuation ranging between $100 million and $200 million, as indicated by founder and CEO Phoenix Peng during a conversation with TechCrunch.
This funding round, co-led by Guosheng Capital and Dalton Venture, with considerable input from Tsing Song Capital, Gobi Ventures, Fourier Intelligence, Liepin, and Seas Capital, was significantly oversubscribed, drawing investor commitments exceeding $58 million, according to Peng.
This funding marks a pivotal moment, being the most substantial early-stage financing within China’s BCI sector.
The capital will facilitate research and development, expand the workforce from 15 to approximately 35 employees by year-end, and establish a manufacturing facility in China. The nascent startup aspires to finalize its initial prototype by the close of the year.
Simultaneously, the worldwide BCI market is witnessing a notable uptick in investments, particularly in ultrasound technology.
Although Gestala stands as the pioneering ultrasound BCI entity in China, it is not globally unique; various ultrasound BCI startups have emerged in the United States, notably Merge Labs, one of the most prominent.
Peng posits that ultrasound technology may herald a new era in brain-computer interfaces, potentially allowing for extensive whole-brain access and novel interaction methods with neural activity.
The founder asserts that non-invasive ultrasound may mitigate one of the most significant hurdles to BCI adoption: the inherent dangers associated with brain surgery.
In comparison to implanted electrode systems, this technology has the ability to monitor a broader swath of the brain, including deep neural circuits.
Employing phased-array ultrasound, the system can accurately stimulate or suppress neural activity sans surgical intervention.
In spite of escalating geopolitical tensions, Peng remains optimistic about the potential for collaborative deep-technology research between the U.S. and China.
“Each nation brings distinct advantages,” Peng remarked. “China boasts substantial clinical research capacity and efficient supply chains, while the U.S. is home to exceptional scientific talent.” He envisions joint initiatives focusing on compiling extensive clinical datasets to bolster global neuroscience research.
Gestala is investigating diverse applications for its technology. Notably, chronic pain management stands as the startup’s primary focus.
Chronic pain afflicts vast demographics across both the U.S. and China, and preliminary academic research indicates that ultrasound stimulation can notably alleviate pain levels, according to Peng.
Further avenues of exploration include mental health disorders such as depression, PTSD, autism, and OCD, alongside stroke rehabilitation efforts.
Additionally, the startup is eyeing long-term targets including Alzheimer’s disease, essential tremor, and Parkinson’s disease. In total, the company is investigating six to eight potential applications, although most remain in early research stages, not yet advancing to clinical trials.
Gestala asserts that its competitive edge over international counterparts lies in speed and scope. By leveraging China’s comprehensive manufacturing ecosystem, the startup anticipates a more rapid transition from development to production compared to many foreign competitors.
Moreover, the company is collaborating with major Chinese hospitals to expedite clinical trials at substantially lower costs—approximately 20% to 33% of comparable studies in the U.S. or Europe.
Concurrently, Gestala is developing an “Ultrasound Brain Bank,” a comprehensive clinical dataset aimed at training AI models to decipher brain signals, thus enhancing future neurological diagnostics.
Source link: Finance.yahoo.com.
